APLT241220P1000
- 0.07
- +0.02+40.00%
Applied Therapeutics Newsroom
Catalyst Watch: FOMC Meeting, Govt. Funding Drama, Earnings for Micron, Nike, and FedEx
Express News | Applied Therapeutics Inc - Joel Marcus Resigns From Applied Therapeutics Board
Wolf Popper LLP Announces Investigation on Behalf of Applied Therapeutics, Inc. Investors
(APLT) - Analyzing Applied Therapeutics's Short Interest
William Blair Maintains Applied Therapeutics(APLT.US) With Buy Rating
Buy Rating Maintained for Applied Therapeutics Amidst SORD Program Potential and Regulatory Challenges
Insiders Could Have Profited By Holding Onto Applied Therapeutics Shares Despite 84% Drop
Optimistic Outlook for Applied Therapeutics Despite FDA Setback
Applied Therapeutics Faces FDA Challenges With Govorestat
Express News | Applied Therapeutics: Following Issuance of a Complete Response Letter by FDA, Received Warning Letter Limited to at-007-1002 Study
Applied Therapeutics Faces Uncertainty After US FDA Rejects NDA for Govorestat in Galactosemia, UBS Says
Netflix To Rally More Than 7%? Here Are 10 Top Analyst Forecasts For Monday
Express News | Applied Therapeutics Inc : UBS Cuts Target Price to $2 From $13
Express News | Applied Therapeutics Inc : UBS Cuts to Neutral From Buy
Applied Therapeutics CRL a 'Major Setback,' Says William Blair
Applied Therapeutics Downgraded to Sector Perform From Outperform at RBC
US stocks closed | The three major indices rose together, the Dow and S&P continued to hit historical highs; most large technology stocks rose, nvidia rose more than 2%, Tesla soared more than 38% in the month, the best performance in nearly two years
US stocks posted weekly gains of over 1%, with the Dow rising by 7.5% in November and the S&P up 5.7%, both achieving the best performance of the year. The Nasdaq accumulated an increase of over 6%, small-cap indices rose by nearly 11%, the chip index rose by 1.5% on Friday but declined monthly, and Tesla saw a monthly increase of over 38%, its best performance in nearly two years.
Express News | Citigroup has raised the target price for applied therapeutics from $11.00 to $13.00.
Applied Therapeutics Is Maintained at Buy by Citigroup
Applied Therapeutics Price Target Raised to $13.00/Share From $11.00 by Citigroup